Harvard Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary

Harvard Bioscience

11/08/2026 14:32

Harvard Bioscience Inc HBIO.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -10 cents.  The mean expectation of two analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -35 cents to -7 cents per share.
Revenue rose 11.1% to $22.73 million from a year ago; analysts expected $21.45 million. 
Harvard Bioscience Inc's reported EPS for the quarter was a loss of 64 cents​.
The company reported a quarterly loss of $2.91 million.
Harvard Bioscience Inc shares had risen by 3.9% this quarter and lost 4.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 50.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy" 
Wall Street's median 12-month price target for Harvard Bioscience Inc is $6.00, about 6.5% below its last closing price of $6.39
This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.21
-0.14
Beat
Mar. 31 2026 
-0.62
-0.33
Beat
Dec. 31 2025 
0.35
0.00
Missed
Sep. 30 2025 
0.05
0.00
Missed